×
About 213 results

ALLMedicine™ Alexander Disease Center

Research & Reviews  82 results

A Study to Evaluate the Safety and Efficacy of ION373 in Patients With Alexander Disease (AxD)
https://clinicaltrials.gov/ct2/show/NCT04849741

Aug 3rd, 2022 - This is a Phase 1-3, multi-center, double-blind, placebo-controlled, multiple-ascending dose (MAD) study in up to 58 patients with AxD. Participants will be randomized in a 2:1 ratio to receive ION373 or matching placebo for a 60-week double-blind...

Symptomatic care of late-onset Alexander disease presenting with area postrema-like syn...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277918
BMC Pediatrics; Zardadi S, Razmara E et. al.

Jul 14th, 2022 - Alexander disease (AxD) is classified into AxD type I (infantile) and AxD type II (juvenile and adult form). We aimed to determine the potential genetic cause(s) contributing to the AxD type II manifestations in a 9-year-old male who presented are...

Novel Glial Fibrillary Acidic Protein Variant in a Probable Adult-Onset Alexander Disease.
https://doi.org/10.1093/jnen/nlac014
Journal of Neuropathology and Experimental Neurology; Mork E, Jamshidi P et. al.

Apr 2nd, 2022 - Novel Glial Fibrillary Acidic Protein Variant in a Probable Adult-Onset Alexander Disease.|2022|Mork E,Jamshidi P,Lee JM,|genetics,genetics,genetics,

A novel in-frame GFAP p.E138_L148del mutation in Type II Alexander disease with atypica...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9178008
European Journal of Human Genetics : EJHG; Kang YR, Lee SH et. al.

Mar 6th, 2022 - Alexander disease (AxD) is a neurodegenerative astrogliopathy caused by mutation in the glial fibrillary acidic protein (GFAP) gene. A 42-year-old Korean man presented with temporary gait disturbance and psychiatric regression after a minor head t...

Anastasis Drives Senescence and Non-Cell Autonomous Neurodegeneration in the Astrogliop...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8944235
The Journal of Neuroscience : the Official Journal of The... Wang L, Bukhari H et. al.

Feb 3rd, 2022 - Anastasis is a recently described process in which cells recover after late-stage apoptosis activation. The functional consequences of anastasis for cells and tissues are not clearly understood. Using Drosophila, rat and human cells and tissues, i...

see more →

Clinicaltrials.gov  2 results

A Study to Evaluate the Safety and Efficacy of ION373 in Patients With Alexander Disease (AxD)
https://clinicaltrials.gov/ct2/show/NCT04849741

Aug 3rd, 2022 - This is a Phase 1-3, multi-center, double-blind, placebo-controlled, multiple-ascending dose (MAD) study in up to 58 patients with AxD. Participants will be randomized in a 2:1 ratio to receive ION373 or matching placebo for a 60-week double-blind...

Evaluation of Outcome Metrics in Alexander Disease
https://clinicaltrials.gov/ct2/show/NCT02714764

Aug 30th, 2021 - Participants will be asked to complete physical examinations including physical therapy, occupational therapy, speech and language therapy, neurocognitive and swallowing assessments. Patients (or caretakers) may be asked to complete questionnaires...

see more →

Patient Education  1 results

Alexander Disease: Leukodystrophy, Neurologica
https://my.clevelandclinic.org/health/diseases/6027-alexander-disease

Apr 26th, 2022 - Overview What is Alexander disease? Alexander disease is an extremely rare nervous system (neurological) disorder. It’s a type of leukodystrophy, conditions that affect white matter in your brain. Alexander disease damages myelin, the fatty white ...

see more →